AZ Iran will add to this footprint following the signing of a comprehensive “Memorandum of Understanding” (MoU) with the Iranian Food and Drug Authority. This MoU includes several strategic projects that will further accelerate access to innovative medicines for Iranian patients, and will strengthen local research and advance scientific collaboration.
AstraZeneca PLC has a U.S. website.
"While Western powers have identified a small group of sectors for Iranian sanction relief, a much wider set of European and U.S. companies—from pharmaceutical firms and medical-equipment makers to food companies and traders—also stands to regain lost Iranian trade as soon as relief measures are formally adopted next month. Western governments singled out Iran's automotive and aviation sectors for temporary sanction relief, while allowing petrochemical exports and trade in gold and other precious metals. But the fine print of the deal also clears the way for GlaxoSmithKline PLC and Sanofi SA, for example, to restart selling many of the drugs they had been forced to cut back on because of increasingly stiff financial sanctions…Pharmaceutical companies Glaxo and AstraZeneca PLC of the U.K. and Sanofi of France reported annual Iranian sales of roughly $32.2 million, $14 million and $13.9 million, respectively, according to their annual SEC reports…A spokeswoman for AstraZeneca said it works in Iran in 'full compliance with the laws and regulations.'" (Wall Street Journal, "Iran Deal Opens Door for Businesses," 12/1/13)